The field of Neuroimmunology, and particularly research surrounding Multiple Sclerosis (MS), has experienced rapid growth and unprecedented innovation over ...
NEW YORK, NY, UNITED STATES, March 24, 2026 /EINPresswire.com/ — Scientists at the Tisch Multiple Sclerosis Research Center ...
Pain was almost ubiquitous among patients with multiple subtypes of multiple sclerosis, finds a study. Pain was almost omnipresent in measured subtypes of multiple sclerosis (MS), where over one-third ...
The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...
Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, ...
A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS). Having a university education was ...
People with MS who carry the APOE4 gene variant show greater signs of nerve damage and cognitive decline than those who don't ...
People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...
New research from Oregon Health & Science University suggests that people with multiple sclerosis, or MS, could benefit from a low-fat diet to improve the fatigue that’s a debilitating, and ...
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results